{"product_id":"transform-60caps","title":"Transform 60caps","description":"\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eProduct name:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Transform — Paragon Pharmatech\u003c\/span\u003e\u003cbr\u003e\u003cstrong\u003e\u003cspan\u003eStrength per capsule:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e 500 mcg Tesofensine + 500 mcg SLU‑PP‑332\u003c\/span\u003e\u003cbr\u003e\u003cstrong\u003e\u003cspan\u003eCapsules per bottle:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e 60 vegetarian capsules\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eOther names:\u003c\/span\u003e\u003c\/strong\u003e\u003cbr\u003e\u003cspan\u003eTesofensine: NS‑2330; triple monoamine reuptake inhibitor\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eSLU‑PP‑332: ERR agonist; estrogen‑related receptor agonist; exercise‑mimetic small molecule\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCAS numbers:\u003c\/span\u003e\u003c\/strong\u003e\u003cbr\u003e\u003cspan\u003eTesofensine: \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003e195875‑84‑4\u003c\/span\u003e\u003c\/strong\u003e\u003cbr\u003e\u003cspan\u003eSLU‑PP‑332: \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003e303760‑60‑3\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eChemical structure (summary):\u003c\/span\u003e\u003c\/strong\u003e\u003cbr\u003e\u003cspan\u003eTesofensine is a bicyclic tetrahydroisoquinoline‑derived compound containing aromatic phenyl substituents and a tertiary amine, enabling blood–brain barrier penetration and interaction with monoamine transporters.\u003c\/span\u003e\u003cbr\u003e\u003cspan\u003eSLU‑PP‑332 is a synthetic heterocyclic small molecule containing fused aromatic and nitrogen‑containing ring systems designed to bind and activate estrogen‑related receptors (ERRα\/ERRγ), nuclear transcription factors involved in mitochondrial metabolism and oxidative phosphorylation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch1\u003e\u003cspan\u003e10 Strong Points \u0026amp; Benefits \u003c\/span\u003e\u003c\/h1\u003e\n\u003col start=\"1\" data-spread=\"false\"\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eTesofensine has demonstrated clinically significant weight reduction in randomized controlled trials, with meaningful improvements in metabolic risk markers.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eTesofensine reduces caloric intake through central appetite regulation while also increasing metabolic expenditure via sympathetic activation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eSLU‑PP‑332 activates ERR pathways that regulate mitochondrial biogenesis, oxidative metabolism, and endurance‑related gene expression.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eERR activation enhances fatty‑acid oxidation and glucose utilization in skeletal muscle and liver in experimental models.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eThe combination provides complementary mechanisms: central appetite modulation and peripheral metabolic activation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eBoth compounds influence mitochondrial function and cellular bioenergetics, which are central to metabolic disease research.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eTesofensine pharmacokinetics and safety have been characterized in controlled human trials.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eSLU‑PP‑332 produces transcriptional changes resembling endurance training adaptations in preclinical research.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eCombination strategies targeting multiple metabolic pathways are increasingly recognized as more effective than single‑mechanism interventions in metabolic research.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eBoth compounds are chemically stable and suitable for precise analytical verification using HPLC and LC‑MS, supporting reproducible research outcomes.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch1\u003e\u003cspan\u003eOverview\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cspan\u003eTransform is a research formulation combining Tesofensine, a centrally acting monoamine reuptake inhibitor investigated for obesity and metabolic disorders, with SLU‑PP‑332, a selective activator of estrogen‑related receptors involved in mitochondrial biogenesis and oxidative metabolism.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTesofensine was initially investigated in neurological research before its metabolic effects were recognized. By inhibiting dopamine, norepinephrine, and serotonin reuptake, Tesofensine enhances satiety signaling and reduces caloric intake while also influencing thermogenesis and energy expenditure.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSLU‑PP‑332 represents a newer class of metabolic modulators that act through nuclear receptor signaling rather than direct receptor agonism in the central nervous system. Estrogen‑related receptors regulate genes controlling mitochondrial respiration, oxidative phosphorylation, and lipid metabolism. Activation of these pathways produces metabolic adaptations similar to endurance training in experimental systems.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe rationale for combining these compounds is based on targeting multiple components of energy balance simultaneously: food intake, metabolic efficiency, mitochondrial function, and substrate utilization. Such multimodal strategies are an emerging theme in metabolic and obesity research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eParagon Pharmatech manufactures Transform capsules under controlled, GMP‑aligned conditions with identity, purity, and potency testing to ensure reproducibility in laboratory and scientific applications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch1\u003e\u003cspan\u003eHow It Works (Mechanisms \u0026amp; Pharmacology)\u003c\/span\u003e\u003c\/h1\u003e\n\u003ch2\u003e\u003cspan\u003eTesofensine Mechanism of Action\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eTesofensine acts primarily as a triple monoamine reuptake inhibitor, blocking dopamine, norepinephrine, and serotonin transporters. This leads to increased synaptic concentrations of these neurotransmitters in brain regions involved in appetite regulation, reward processing, and satiety.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eEnhanced norepinephrine signaling increases sympathetic nervous system activity, contributing to increased thermogenesis and lipolysis. Dopamine signaling influences reward‑driven feeding behavior, reducing compulsive eating patterns in experimental settings. Serotonin contributes to satiety signaling and appetite suppression.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePharmacokinetic studies show Tesofensine has a relatively long elimination half‑life and active metabolites, resulting in sustained pharmacodynamic effects. Brain imaging studies demonstrate modulation of neural activity in hypothalamic and limbic regions involved in feeding behavior.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eSLU‑PP‑332 Mechanism of Action\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eSLU‑PP‑332 activates estrogen‑related receptors, particularly ERRα and ERRγ. These nuclear receptors regulate transcription of genes involved in mitochondrial respiration, oxidative phosphorylation, fatty‑acid oxidation, and endurance metabolism.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eActivation of ERR pathways increases expression of PGC‑1α and downstream regulators of mitochondrial biogenesis. Experimental studies demonstrate increased oxygen consumption, improved endurance capacity, and enhanced metabolic flexibility in animal models.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eERR activation also influences glucose uptake, skeletal muscle fiber composition, and lipid utilization. These effects support improved metabolic efficiency and resilience in models of metabolic stress.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eCombined Mechanistic Model\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eThe combined formulation integrates complementary mechanisms:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eReduced caloric intake through central appetite regulation\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eIncreased mitochondrial capacity and oxidative metabolism\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eEnhanced fatty‑acid oxidation and glucose handling\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eImproved metabolic flexibility and energy balance\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThis multi‑pathway approach reflects current scientific understanding that metabolic diseases involve multiple interconnected systems including central nervous regulation, mitochondrial function, and endocrine signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch1\u003e\u003cspan\u003eWhat Studies Have Shown \u003c\/span\u003e\u003c\/h1\u003e\n\u003ch2\u003e\u003cspan\u003eTesofensine Clinical Studies\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eRandomized controlled trials in overweight and obese subjects demonstrated significant weight reduction compared with placebo. In several studies, subjects receiving Tesofensine experienced weight reductions in the range of approximately 5–12% over periods of several months, accompanied by reductions in waist circumference and improvements in lipid and glycemic markers.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eClinical trials also documented reductions in caloric intake and increased satiety scores in controlled feeding environments. Neuroimaging research showed changes in brain regions associated with appetite regulation and reward processing, supporting the mechanistic basis for reduced food intake.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAdverse effects reported in clinical studies included dry mouth, insomnia, and mild increases in heart rate. Cardiovascular monitoring was incorporated into protocols to evaluate potential sympathomimetic effects.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eSLU‑PP‑332 Preclinical Studies\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eExperimental studies in rodents demonstrated increased endurance capacity, enhanced mitochondrial respiration, and upregulation of genes associated with oxidative metabolism following administration of SLU‑PP‑332.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn models of diet‑induced obesity, treatment resulted in reductions in adiposity and improvements in glucose tolerance and insulin sensitivity. Tissue analysis revealed increased mitochondrial density and oxidative enzyme activity in skeletal muscle.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eGene expression analyses confirmed activation of pathways regulating fatty‑acid oxidation, mitochondrial respiration, and energy metabolism, consistent with exercise‑like adaptations.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eMechanistic and Translational Research\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eResearch into estrogen‑related receptors has established their role in metabolic regulation, mitochondrial function, and endurance physiology. Activation of these pathways produces systemic metabolic changes that parallel adaptations seen in aerobic training.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTesofensine research has demonstrated consistent central appetite‑modulating effects, making it one of the most potent investigational anti‑obesity agents studied in controlled trials.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eCombination Rationale\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eAlthough direct clinical trials of this exact combination are limited, scientific literature supports the concept that combining agents that reduce caloric intake with those that increase metabolic capacity may produce complementary effects on energy balance and body composition.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eEvidence synthesis therefore indicates strong clinical evidence for Tesofensine, strong mechanistic and preclinical evidence for SLU‑PP‑332, and a scientifically plausible rationale for combination approaches targeting multiple metabolic pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch1\u003e\u003cspan\u003eUsage \u0026amp; Quality Compliance \u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cspan\u003eTransform capsules are manufactured under GMP‑aligned conditions. Each batch undergoes:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eIdentity testing by HPLC or LC‑MS\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003ePotency assay for both active ingredients\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eResidual solvent testing\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eHeavy metal analysis\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eMicrobiological testing\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eStability testing\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eResearch protocols may include monitoring of body weight, metabolic panels, lipid profiles, glucose tolerance, cardiovascular parameters, and mitochondrial biomarkers where relevant.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRandomized, double‑blind, placebo‑controlled designs are recommended to minimize bias and improve reproducibility in metabolic research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch1\u003e\u003cspan\u003eSafety Note\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cspan\u003eTesofensine may produce sympathomimetic effects including increased heart rate, insomnia, dry mouth, and mild increases in blood pressure. Cardiovascular monitoring is recommended in experimental settings.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSLU‑PP‑332 remains investigational, and long‑term human safety data are limited. Nuclear receptor modulation may influence multiple metabolic pathways, requiring careful dosing and monitoring in research protocols.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContraindications for experimental protocols may include significant cardiovascular disease, uncontrolled hypertension, severe metabolic disorders, or concurrent investigational metabolic agents.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch1\u003e\u003cspan\u003eFull Reference List \u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cspan\u003eAstrup A et al. Tesofensine in the treatment of obesity: randomized controlled trial. \u003c\/span\u003e\u003ca disabled\u003e\u003cspan\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/20300078\/\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHjorth S et al. Tesofensine pharmacology and monoamine reuptake inhibition. \u003c\/span\u003e\u003ca disabled\u003e\u003cspan\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/17591541\/\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBillon C, Auwerx J. Nuclear receptors and mitochondrial function in metabolic disease. \u003c\/span\u003e\u003ca disabled\u003e\u003cspan\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/22498809\/\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRangwala SM, Wang X. Estrogen‑related receptors and energy metabolism. \u003c\/span\u003e\u003ca disabled\u003e\u003cspan\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/18713868\/\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eZhang Y et al. ERR agonists and exercise‑mimetic metabolic effects. \u003c\/span\u003e\u003ca disabled\u003e\u003cspan\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/37651246\/\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePGC‑1α and mitochondrial biogenesis review. \u003c\/span\u003e\u003ca disabled\u003e\u003cspan\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/15254340\/\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003e© Paragon Pharmatech — Educational Material 2025. For scientific and educational purposes only.\u003cbr\u003e\u003cbr\u003e\u003cspan style=\"color: #ff2a00;\"\u003eRemember, this product is intended for research purposes only and should not be used for human consumption without proper medical guidance. As with any supplement, it is important to prioritize your health and safety, and to consult with a healthcare professional if you have any underlying health concerns before incorporating this product into your routine.\u003c\/span\u003e\u003cbr\u003e\u003cspan style=\"color: #ff2a00;\"\u003eThis product is not a food product. By acquiring this product, you are in full knowledge that it’s not a food, nor is it for human consumption and it’s for market research purposes only\u003c\/span\u003e\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv style=\"display: none;\" id=\"sconnect-is-installed\"\u003e2.14.0.0\u003c\/div\u003e\n\u003cdiv style=\"display: none;\" id=\"sconnect-is-installed\"\u003e2.14.0.0\u003c\/div\u003e\n\u003cdiv style=\"display: none;\" id=\"sconnect-is-installed\"\u003e2.14.0.0\u003c\/div\u003e","brand":"ProSuppz.Com","offers":[{"title":"Default Title","offer_id":56751655715148,"sku":"PL005","price":96.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0790\/2871\/5852\/files\/FWTransform2.png?v=1771413142","url":"https:\/\/prosuppz.com\/products\/transform-60caps","provider":"ProSuppz.Com","version":"1.0","type":"link"}